News

Pharmabiz5h
AstraZeneca & Daiichi Sankyo’s Datroway gets US approval for patients with previously treated advanced EGFR-mutated NSCLC
AstraZeneca & Daiichi Sankyo’s Datroway gets US approval for patients with previously treated advanced EGFR-mutated NSCLC ...
PharmExec17h
FDA Grants Accelerated Approval to AstraZeneca, Daiichi Sankyo’s Datroway for Previously Treated, Locally Advanced or Metastatic EGFR-Mutated NSCLC
Approval was based on results from the Phase II TROPION-Lung05 trial, which showed that Datroway demonstrated a strong ...
pharmaphorum20h
AZ, Daiichi get Datroway nod in lung cancer on second try
AstraZeneca and Daiichi Sankyo's TROP2-directed antibody-drug conjugate (ADC) Datroway has been granted accelerated approval ...
Fierce Pharma20h
AZ, Daiichi's Datroway scores its 2nd FDA approval—this time in lung cancer subset
The FDA has blessed AstraZeneca and Daiichi Sankyo’s Datroway to treat patients with locally advanced or metastatic epidermal ...